Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E30.71 EPS (ttm)2.01 Insider Own0.16% Shs Outstand1.63B Perf Week0.55%
Market Cap100.95B Forward P/E16.04 EPS next Y3.86 Insider Trans0.19% Shs Float1.63B Perf Month3.08%
Income3.30B PEG2.80 EPS next Q0.89 Inst Own74.20% Short Float0.87% Perf Quarter12.58%
Sales21.60B P/S4.67 EPS this Y-10.90% Inst Trans1.30% Short Ratio2.53 Perf Half Y-0.95%
Book/sh7.54 P/B8.20 EPS next Y7.11% ROA1.10% Target Price59.56 Perf Year-2.17%
Cash/sh3.72 P/C16.62 EPS next 5Y10.98% ROE2.90% 52W Range49.96 - 70.05 Perf YTD0.88%
Dividend1.60 P/FCF66.29 EPS past 5Y15.30% ROI20.20% 52W High-11.75% Beta0.97
Dividend %2.59% Quick Ratio1.30 Sales past 5Y3.30% Gross Margin70.50% 52W Low23.74% ATR0.88
Employees23700 Current Ratio1.40 Sales Q/Q10.90% Oper. Margin20.90% RSI (14)60.75 Volatility1.78% 1.39%
OptionableYes Debt/Eq0.60 EPS Q/Q-59.30% Profit Margin1.70% Rel Volume1.06 Prev Close61.59
ShortableYes LT Debt/Eq0.46 EarningsOct 25 BMO Payout684.10% Avg Volume5.57M Price61.82
Recom2.50 SMA201.44% SMA503.52% SMA2004.21% Volume5,904,413 Change0.37%
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Sep-25-18 10:10AM  Why the Earnings Surprise Streak Could Continue for Bristol-Myers (BMY) Zacks
08:29AM  Trump Clinches Trade Deal With South Korea: 6 Winning Picks Zacks
Sep-24-18 10:25AM  AbbVie/Roche's Leukemia Drugs Combo Gets CHMP Backing in EU Zacks
10:19AM  AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk Zacks
Sep-20-18 07:52PM  Flexible labs, co-working space: Big Pharma is rethinking real estate American City Business Journals
Sep-19-18 06:03PM  Bristol-Myers' MM Drug Empliciti Application Validated by EMA Zacks
09:15AM  Is Bristol-Myers Squibb (BMY) a Great Dividend Play? Zacks
08:48AM  Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff Zacks
Sep-18-18 09:17AM  Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern Zacks
08:13AM  Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth? Zacks
06:59AM  European Medicines Agency Validates Bristol-Myers Squibbs Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma Business Wire
Sep-16-18 06:30PM  Bristol-Myers Squibb's New Psoriasis Drug Has Echoes of Humira GuruFocus.com
Sep-14-18 10:02AM  Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus Zacks
Sep-13-18 10:54AM  Bristol-Myers Squibb Company (NYSE:BMY) Is Trading At A 23.98% Discount Simply Wall St.
Sep-12-18 04:10PM  Bristol-Myers Squibb Announces Dividend Business Wire
12:06PM  Bristol-Myers plaque psoriasis drug shows promise in mid-stage trial Reuters
11:56AM  Apple under pressure, Tiffany moves higher, Bristol-Myers Squibb dips Yahoo Finance
11:25AM  The Outlook for AstraZeneca Is Positive, But Its Too Early to Pull the Trigger InvestorPlace
09:55AM  Merck's Antibacterial Drug Succeeds in Label Expansion Study Zacks
09:45AM  Immunotherapy for NSCLC: 4 Large-Cap Pharma Stocks in Focus Zacks
09:44AM  Bristol-Myers (BMY) Reports Phase II Data on Psoriasis Drug Zacks
07:39AM  Stocks making the biggest move premarket: AAPL, NIO, GILD, TEVA, BMY & more CNBC
02:01AM  Bristol-Myers Squibbs Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial Business Wire
Sep-09-18 06:31AM  Is Bristol-Myers Squibb Company a Buy? Motley Fool
Sep-07-18 09:51AM  The Zacks Analyst Blog Highlights: Caterpillar, D.R. Horton, Bristol-Myers Squibb, athenahealth and BJ's Restaurants Zacks
09:30AM  Why Is Nektar (NKTR) Up 11.2% Since Last Earnings Report? Zacks
Sep-06-18 03:00PM  Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference Business Wire
02:25PM  Here's Why Nektar Therapeutics Jumped 26.4% in August Motley Fool
12:54PM  Novartis to Sell Sandoz's Dermatology Business to Aurobindo Zacks
12:49PM  Biotech Dives After Experimental Lung Cancer Regimen Disappoints Investor's Business Daily
10:09AM  September Bogging You? Look at the Best 9-Month Run Instead Zacks
06:59AM  Bristol-Myers Squibb to Announce Results for Third Quarter 2018 on October 25 Business Wire
Sep-05-18 06:07PM  J&J Submits NDA to the FDA for Depression Drug in Adults Zacks
04:17PM  This Biotech Got A Bullish Pop On Its Experimental Cancer Regimen Investor's Business Daily
12:37PM  Why Bristol-Myers Squibb Is a Great Dividend Stock InvestorPlace
09:11AM  The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Cleveland-Cliffs, Callaway Golf, SkyWest and Vishay Intertechnology Zacks
06:59AM  Bristol-Myers Squibb Kicks Off Coast 2 Coast 4 Cancer Ride to Fundraise for the V Foundation for Cancer Research Business Wire
Sep-04-18 02:27PM  5 Top Stocks to Challenge a Notorious September InvestorPlace
10:08AM  AstraZeneca Up This Year So Far on Favorable Pipeline Updates Zacks
09:34AM  The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Qualcomm, Citigroup, Diageo and Anthem Zacks
07:56AM  5 Top Stocks to Challenge a Notorious September Zacks
Sep-03-18 09:15AM  Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Zacks
Aug-31-18 03:53PM  Merck (MRK) Receives FDA Approval for Two HIV Medicines Zacks
01:46PM  Top Stock Reports for Bristol-Myers, Qualcomm & Citigroup Zacks
08:39AM  4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline Zacks
Aug-30-18 08:54AM  Is Beaten-Down Exelixis, Inc. a Buy Now? Motley Fool
06:59AM  U.S. Food and Drug Administration Accepts Bristol-Myers Squibbs Application for Sprycel (dasatinib) in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Business Wire
Aug-29-18 09:43AM  Novartis' Tafinlar/Mekinist Combo Gets EU Nod for 3rd Disease Zacks
09:30AM  Pfizer Stock Up This Year So Far: What's Going in its Favor? Zacks
Aug-28-18 09:00AM  Bristol-Myers Squibb Appoints Christopher Boerner Executive Vice President and Chief Commercial Officer Business Wire
Aug-27-18 11:30AM  Bristol-Myer Stock May Jump 9% on Rising Forecasts Investopedia
08:13AM  The Zacks Analyst Blog Highlights: Amazon, Microsoft, Apple, Bristol-Myers and Celgene Zacks
Aug-24-18 09:51AM  R&D Spending Hits the Fastest Pace in 12 Years: Top 5 Winners Zacks
09:44AM  Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review Zacks
08:54AM  Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs Zacks
Aug-23-18 11:00AM  Pfizer Amends Xtandi Study Protocols to Speed Up Completion Zacks
10:04AM  J&J to Appeal as Judge Confirms Jury Order in Talc Case Zacks
07:52AM  Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio Zacks
06:59AM  U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibbs Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Business Wire
Aug-22-18 06:17PM  Bill Nygren's Top 3 Buys in 2nd Quarter GuruFocus.com
11:42AM  Bristol-Myers Is Confronting Overhead Resistance and a Lack of Aggressive Buying TheStreet.com
09:45AM  Allergan Falls on FDA's Rejection of Uterine Fibroids Drug Zacks
Aug-21-18 07:12AM  The Cost of Cures: How Investing in Biotech Stocks Could Soon Be Radically Changed Motley Fool
Aug-20-18 04:50PM  Bristol-Myers' Opdivo Gets FDA Nod for Small Cell Lung Cancer Zacks
11:10AM  Roche's Lung Cancer Drug Alecensa Gets Approval in China Zacks
08:26AM  Better Buy: Celgene Corporation vs. Bristol-Myers Squibb Motley Fool
Aug-17-18 08:03AM  FDA approves Bristol-Myers' Opdivo for small cell lung cancer Reuters
07:09AM  Bristol-Myers wins FDA approval for Opdivo as treatment for small cell lung cancer MarketWatch
06:59AM  U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as the First New Medication in Nearly 20 Years for Certain Patients with Previously Treated Small Cell Lung Cancer Business Wire
Aug-16-18 09:37AM  The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait Benzinga
Aug-15-18 04:21PM  Heat Biologics Stock Is a Worthwhile, Speculative Bet InvestorPlace
02:58PM  The stocks you wanted to know about today CNBC Videos
Aug-14-18 10:06AM  5 Top-Ranked S&P 500 Stocks to Buy on Market Dip Zacks
06:52AM  Zacks.com featured highlights include: United States Cellular, Molina Healthcare, Archer Daniels, Bristol-Myers and Callaway Golf Zacks
06:02AM  Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb Motley Fool
Aug-13-18 08:13AM  Pick These 5 Stocks With Remarkable Relative Price Strength Zacks
07:38AM  The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers Zacks
Aug-12-18 04:52PM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs Benzinga
Aug-10-18 05:39PM  Edited Transcript of BMY earnings conference call or presentation 26-Jul-18 2:30pm GMT Thomson Reuters StreetEvents
Aug-09-18 09:52AM  Nektar (NKTR) Q2 Earnings In Line, Product Sales Down Y/Y Zacks
Aug-08-18 08:10AM  Report: Developing Opportunities within Cytosorbents, Nasdaq, Mastercard, Maxim Integrated Products, Bristol-Myers Squibb, and Equity Lifestyle Properties Future Expectations, Projections Moving into 2018 GlobeNewswire
Aug-07-18 09:50AM  Q2 Earnings Drive Pharma ETFs Higher Zacks
09:30AM  BMY vs. NVO: Which Stock Is the Better Value Option? Zacks
Aug-06-18 09:09AM  The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis Zacks
Aug-03-18 11:23AM  Pharma Stock Roundup: PFE Dominates Headlines, BMY Drug Gets EU Approval Zacks
Aug-02-18 02:10PM  Moody's: US drug makers face heightened pricing pressure as regulatory risks pick up steam Moody's
12:50PM  Here's Why Exelixis Stock Jumped Higher Today Motley Fool
Aug-01-18 05:24PM  The opioid drug that addicts don't like could be approved next spring American City Business Journals
Jul-31-18 08:20AM  Today's Research Reports on Trending Tickers: Bristol-Myers Squibb and Allergan ACCESSWIRE
06:59AM  European Commission Approves Bristol-Myers Squibbs Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection Business Wire
Jul-27-18 12:16PM  Merck profit beats, but Keytruda sales fail to impress Reuters
11:01AM  Why Bristol-Myers Squibb (BMY) is a Top Dividend Stock Zacks
07:48AM  [$$] Merck overtakes rival on immunotherapy drug sales Financial Times
Jul-26-18 12:52PM  Bristol-Myers cancer ruling hits shares after strong earnings Reuters
11:11AM  Bristol-Myers (BMY) Beats on Q2 Earnings, Raises Outlook Zacks
10:59AM  Bristol-Myers to get negative CHMP opinion on renal cancer drugs Reuters
10:30AM  Bristol-Myers profit tops Street view, raises full-year forecast Reuters
09:10AM  Bristol-Myers Squibb (BMY) Surpasses Q2 Earnings and Revenue Estimates Zacks
07:40AM  Bristol-Myers: 2Q Earnings Snapshot Associated Press
07:36AM  Bristol-Myers shares lift on Q2 profit, revenue beats MarketWatch
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a collaboration agreement with Nektar Therapeutics, Illumina, Inc., Janssen Pharmaceuticals, Inc., and Advantagene, Inc., as well as Tsinghua University. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dubow AdamChief Compliance & Ethics OffiSep 03Option Exercise0.00797015,495Sep 05 04:49 PM
Santiago Karen MurphyControllerSep 01Option Exercise0.0064104,057Sep 05 04:49 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510050,168Aug 03 05:05 PM
Biondi PaulSVP, Head of Strategy & BDJul 01Option Exercise0.001,46101,461Jul 03 09:24 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400292,822May 08 05:05 PM
Paliwal Dinesh CDirectorApr 30Buy52.404,770249,9488,027May 02 04:05 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0012,367018,267Apr 05 04:37 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00219,2110333,970Mar 13 04:56 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0036,044075,370Mar 13 04:56 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,043086,932Mar 13 04:56 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0034,681053,132Mar 13 04:57 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0039,235062,028Mar 13 04:55 PM
Santiago Karen MurphyControllerMar 10Option Exercise0.004,40704,456Mar 13 04:55 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0091,3180363,739Mar 13 04:53 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,2750136,441Mar 13 04:54 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0068,8960488,677Mar 13 04:54 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 23Option Exercise22.1437,460829,364302,348Feb 27 04:45 PM
Samuels Theodore R. IIDirectorDec 15Buy62.304,000249,18722,000Dec 18 04:21 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerDec 12Sale63.245,300335,1729,251Dec 13 05:31 PM
LEUNG SANDRAEVP, General CounselDec 04Option Exercise22.14156,5823,466,725584,373Dec 05 06:15 PM
LEUNG SANDRAEVP, General CounselDec 04Sale63.37156,5829,922,601427,791Dec 05 06:15 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010267,770Dec 05 06:15 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494068,166Nov 03 04:32 PM